As ASE celebrates its 50th anniversary in Nashville, Dr. Jordan Strom discusses the latest in echocardiography research to be presented at the scientific sessions meeting along with new guidelines, the Kalmanson Lecture, and ongoing challenges in workforce development.
Prenatal chlorpyrifos associated with magnetic resonance imaging changes, hypoperfusion, and motor slowing—without age/sex moderation, mediation, or connectivity effects.
Without a defined standard of care for tapering GLP-1 medications, physicians must navigate patient management amid insurer restrictions and high discontinuation rates
The FDA approved Bildyos and Bilprevda are providing new options comparable to Prolia and Xgeva for osteoporosis, cancer-related bone disease, and other skeletal conditions.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
The FDA has approved rilzabrutinib (Wayrilz) as the first Bruton’s tyrosine kinase inhibitor for adults with chronic or persistent immune thrombocytopenia who have had an insufficient response to prior therapy.